These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15934495)

  • 61. A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis.
    Hotton KM; Khorsand M; Hank JA; Albertini M; Kim KM; Wilding G; Salamat MS; Larson M; Sondel P; Schiller JH
    Cancer; 2000 Apr; 88(8):1892-901. PubMed ID: 10760767
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma.
    Boasberg PD; Hoon DS; Piro LD; Martin MA; Fujimoto A; Kristedja TS; Bhachu S; Ye X; Deck RR; O'Day SJ
    J Invest Dermatol; 2006 Dec; 126(12):2658-63. PubMed ID: 16946711
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for patients with cancer.
    Gitlitz BJ; Figlin RA; Kiertscher SM; Moldawer N; Rosen F; Roth MD
    J Immunother; 2003; 26(2):171-8. PubMed ID: 12616109
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF.
    Si Z; Hersey P; Coates AS
    Melanoma Res; 1996 Jun; 6(3):247-55. PubMed ID: 8819128
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.
    Agarwala SS; Glaspy J; O'Day SJ; Mitchell M; Gutheil J; Whitman E; Gonzalez R; Hersh E; Feun L; Belt R; Meyskens F; Hellstrand K; Wood D; Kirkwood JM; Gehlsen KR; Naredi P
    J Clin Oncol; 2002 Jan; 20(1):125-33. PubMed ID: 11773161
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Adjuvant GM-CSF improves survival in high-risk stage iiic melanoma: a single-center Study.
    Grotz TE; Kottschade L; Pavey ES; Markovic SN; Jakub JW
    Am J Clin Oncol; 2014 Oct; 37(5):467-72. PubMed ID: 23428946
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.
    Cham J; Zhang L; Kwek S; Paciorek A; He T; Fong G; Oh DY; Fong L
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376721
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
    Green DS; Bodman-Smith MD; Dalgleish AG; Fischer MD
    Br J Dermatol; 2007 Feb; 156(2):337-45. PubMed ID: 17223875
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCRβ Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood.
    Aris M; Bravo AI; Garcia Alvarez HM; Carri I; Podaza E; Blanco PA; Rotondaro C; Bentivegna S; Nielsen M; Barrio MM; Mordoh J
    Front Immunol; 2019; 10():2213. PubMed ID: 31620131
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combination Immunotherapy for Melanoma.
    Kaufman HL
    JAMA Oncol; 2015 Jun; 1(3):387-8. PubMed ID: 26181189
    [No Abstract]   [Full Text] [Related]  

  • 71. Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma.
    Tarhini AA; Joshi I; Garner F
    Immunotherapy; 2021 Aug; 13(12):1011-1029. PubMed ID: 34157863
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III: Cytokine studies.
    Haworth C; O'Reilly SM; Chu E; Rustin GJ; Feldmann M
    Br J Cancer; 1993 Jun; 67(6):1346-50. PubMed ID: 8512819
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Multiple sclerosis onset after granulocyte macrophage colony-stimulating factor withdrawal.
    Chong J; Cohen M; Waubant E
    Mult Scler Relat Disord; 2018 Feb; 20():178-180. PubMed ID: 29414294
    [TBL] [Abstract][Full Text] [Related]  

  • 74. GM-CSF/Ipilimumab combination extends melanoma survival.
    Cancer Discov; 2013 Jul; 3(7):OF6. PubMed ID: 23847381
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy.
    Zehntner S; Townsend W; Parkes J; Schmidt C; Down M; Bell J; Mulligan R; O'Rourke M; Ellem K; Thomas R
    Pathology; 1999 May; 31(2):116-22. PubMed ID: 10399166
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream.
    Garcia MS; Ono Y; Martinez SR; Chen SL; Goodarzi H; Phan T; Wehrli LN; Miyamura Y; Fung MA; Maverakis E
    Melanoma Res; 2011 Jun; 21(3):235-43. PubMed ID: 21464773
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Adjuvant therapy for melanoma: a surgical perspective.
    Sondak VK; Gonzalez RJ; Kudchadkar R
    Surg Oncol Clin N Am; 2011 Jan; 20(1):105-14. PubMed ID: 21111961
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma.
    Killock D
    Nat Rev Clin Oncol; 2015 Aug; 12(8):438. PubMed ID: 26077044
    [No Abstract]   [Full Text] [Related]  

  • 79. T Cells Dominate the Local Immune Response Induced by Intralesional IL-2 in Combination with Imiquimod and Retinoid for In-Transit Metastatic Melanoma.
    Ogawa H; Luxardi G; Kirane A; Kulkarni R; Monjazeb AM; Cheng MY; Ma C; Maverakis E
    J Invest Dermatol; 2018 Jun; 138(6):1442-1445. PubMed ID: 29291382
    [No Abstract]   [Full Text] [Related]  

  • 80. Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients.
    Posch C; Weihsengruber F; Bartsch K; Feichtenschlager V; Sanlorenzo M; Vujic I; Monshi B; Ortiz-Urda S; Rappersberger K
    Br J Cancer; 2014 Mar; 110(6):1427-32. PubMed ID: 24518593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.